investor.regeneron.com
Nice gig if you can qualify. Some say advice is what your pay for it.
"On September 9, 2016, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Bonnie L. Bassler, Ph.D. as a Class I director and Huda Y. Zoghbi, M.D. as a Class II director to fill the two existing vacancies on the Board. Drs. Bassler and Zoghbi have also been appointed to serve on the Corporate Governance and Compliance Committee and the Technology Committee of the Board. In accordance with the requirements of the New York Business Corporation Law, Drs. Bassler and Zoghbi will hold office until the 2017 Annual Shareholder Meeting of the Company, which is expected to be held on June 9, 2017."
"Each of Drs. Bassler and Zoghbi will receive compensation from the Company for her service as a director in accordance with the Company’s compensation practices for non-employee directors, including an annual retainer of $55,000 and an annual $10,000 retainer for each committee on which she serves. On the day of their election, Drs. Bassler and Zoghbi were each granted an option to purchase 15,353 shares of the Company’s common stock, $0.001 par value per share, under the Company’s 2014 Long-Term Incentive Plan (the “ Plan ”), and they will also be eligible for annual awards to non-employee directors under the Plan." |
